Accession Number : AD1002317

Title :   Translational Advancement of Somatostatin Gene Delivery for Disease Modification and Cognitive Sparing in Intractable Epilepsy

Descriptive Note : Technical Report,01 Sep 2014,31 Aug 2015

Corporate Author : University of Florida Gainesville United States

Personal Author(s) : King,Michael A ; Ormerod,Brandi K ; Carney,Paul R

Full Text :

Report Date : 01 Sep 2015

Pagination or Media Count : 18

Abstract : Stimulation at current levels initially without effect gradually produce a persistent state where severe seizures occur reliably. Animals tested during the reporting period establish that somatostatin gene delivery after development of maximal seizure susceptibility can produce complete amelioration of a seizure-prone state. The therapeutic effect is essentially all or nothing. The responder rate is 30-40%, below the 70% observed when gene delivery preceded kindling, but comparable to extant antiepileptic medication. Responder and nonresponder cohorts cannot be explained by variation in injection placement, transduction efficiency, electrographic seizure variables, effects on seizure stimulated brain stem cell division or differentiation, or obvious brain pathology. Kindling increased new cell generation in hippocampus, with a bias toward non-neuronal phenotypes, and somatostatin gene delivery uniformly suppressed this regardless of therapeutic efficacy against seizures.


Distribution Statement : APPROVED FOR PUBLIC RELEASE